For example, the immunodominant region of NY‐ESO‐1 contains the epitope NY‐ESO‐1157‐165 which is frequently recognized by HLA‐A*02+ HCC patients.12 However, given that only 58% of patients with a response to the corresponding NY‐ESO‐1‐peptide were HLA‐A*02+, it is likely that this region of NY‐ESO‐1 contains additional, unknown CD8+ T‐cell epitopes restricted by other HLA‐molecules. This evidence concerns the gene CD8A and hepatocellular carcinoma.